Coeur d'Alene Hematology and Breast Cancer Conference

Coeur d'Alene, ID US
March 1, 2024 to March 2, 2024

The Coeur d'Alene Hematology and Breast Cancer Conference is a CME-accredited, in-person hematology oncology conference featuring leading hematology and breast cancer experts. Expert faculty will place key abstract findings from the 65th ASH Annual Meeting (ASH2023) and the San Antonio Breast Cancer Symposium (SABCS2023) into clinical context and discuss how the results may change the current standards of care for patients with benign and malignant hematologic disorders and breast cancer. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

This conference allows attendees an opportunity to discuss current research and advances in the field of hematologic disorders and breast cancer with colleagues and key opinion leaders. The goals of this conference are to review and critically assess the results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients. 

 

Target Audience

  • Hematologists, Oncologists
  • Surgeons
  • Radiation Oncologists
  • Physician Assistants/Nurse Practitioners
  • Pharmacists
  • Nurses

Conference Chair

Binay Shah, MD - Binaytara Foundation

VENUE INFORMATION

A limited number of rooms have been booked at The Coeur D'Alene Resort at a discounted nightly rate of $195 per room for this conference's attendees and sponsors. Please book your room at the link here by January 20th to receive the discounted group rate. 

Learning Objectives

  1. Review data presented at the ASH2023 and SABCS2023 & discuss their applications in clinical settings.    
  2. Choose new therapeutic options for treating benign and malignant hematologic disorders & breast cancer, understanding appropriate indications and contraindications to these therapeutic approaches.
  3. Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care in hematology and breast cancer.
  4. Integrate evolving diagnostic, prognostic, and therapeutic approaches to managing hematologic disorders and breast cancer patients.
  5. Individualize management of patients based on emerging data from clinical trials and evolving expert guidelines.

GLOBAL ONCOLOGY PROJECT

To learn more about our ongoing project building a 200-bed cancer hospital in Nepal:

Course summary
Available credit: 
  • 8.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.25 Contact Hours.
Course opens: 
10/31/2023
Course expires: 
06/07/2024
Event starts: 
03/01/2024 - 5:00pm PST
Event ends: 
03/02/2024 - 4:30pm PST
Cost:
$200.00

DAY 1 - March 1st, 2024

All times are listed in Pacific Time (PT)

04:00 PM – 04:45 PM: Registration/Networking & Exhibits


04:45 PM – 05:00 PM: Opening remarks


05:00 PM – 06:30 PM: Session 1 – Case-based discussion

Moderator: Aaron Goodman, MD

Case 1 – Bleeding disorder - Doris Quon, MD, PhD

Case 2 – Clotting disorder - George Rodgers, MD, PhD

Case 3 – Anemia - Corliss Newman, MD

Case 4 – Smoldering Myeloma - Aaron Goodman, MD


06:30 PM – 07:15 PM: Networking/Reception & Exhibits


DAY 2 - March 2nd, 2024

07:00 AM – 07:55 AM: Breakfast & Exhibits


08:00 AM – 09:30 AM: Session 2

Moderator: Rangaswamy Chintapatla, MD

08:00 AM – 08:25 AM: MDS/Acute Leukemia - Roland Walter, MD, PhD, MS

08:25 AM – 08:50 AM: Myeloproliferative neoplasms and CML - Tsewang Tashi, MD

08:50 AM – 09:15 AM: Cellular therapy - Christopher D'Angelo, MD

09:15 AM – 09:30 AM: Q & A


09:30 AM – 10:00 AM:  Break & exhibits


10:00 AM – 11:45 AM: Session 3

Moderator: Basir Haque, MD

10:00 AM – 10:25 AM: Lymphoma - Steven Bair, MD

10:25 AM – 10:50 AM: Chronic lymphocytic leukemia - Haifaa Abdulhaq, MD

10:50 AM – 11:15 AM: Multiple myeloma - Amandeep Godara, MD

11:15 AM – 11:45 AM: Q & A


11:45 AM - 12:45 PM: Lunch & exhibits


12:45 PM - 02:30 PM: Session 4

Moderator: Mirela Andrei, MD

12:45 PM - 01:10 PM: Hormone receptor positive breast cancer - Jennifer Specht, MD  

01:10 PM - 01:35 PM: HER2 positive breast cancer - Mark Pegram, MD

01:35 PM - 02:00 PM: Triple negative and HER2 low breast cancer - Mei Wei, MD

02:00 PM – 02:30 PM: Q & A


02:30 PM – 02:45 PM: Break & exhibits


02:45 PM – 04:30 PM: Session 5

Moderator: Deepthi Kodali, MD

02:45 PM – 03:10 PM: Radiotherapy – best breast practice - O. Kenneth Macdonald, MD

03:10 PM – 03:35 PM: Updates in surgical approach – best breast practice - Stephanie Moline, MD, FACS

03:35 PM – 03:50 PM: Q & A

03:50 PM – 04:30 PM: Case-based discussion

Moderator: Fengting Yan, MD, FACP

Case 1 – DCIS - Fengting Yan, MD, FACP

Case 2 – Inflammatory breast cancer - Oliver Batson, MD

Case 3 – Metaplastic breast cancer - Kristine Rinn, MD


04:30 PM – 04:35 PM: Adjourn

The Coeur d'Alene Resort
115 S 2nd St
Coeur d'Alene, ID 83814
United States

A limited number of rooms have been booked at The Coeur D'Alene Resort at a discounted nightly rate of $195 per room for this conference's attendees and sponsors. Please book your room at the link here by January 20th to receive the discounted group rate. 

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Session Chair(s)

Mirela Andrei

has no relevant financial relationships to disclose at this time.

Basir Haque, MBBS, MD, FACP

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Haifaa Abdulhaq, Clinical Professor, UCSF. Director of Hematology, UCSF Fresno. Director of Hematolog/Oncology Fellowship, UCSF Fresno

has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Morphosys;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Kite;.

Steven Bair, MD

has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with TG Therapeutics;.
has a financial relationship (Independent contractor) with Acellx;.

Christopher D'Angelo, MD

has a financial relationship (Grant Or Contract) with Ono Pharma Inc;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Grant Or Contract) with Beigene;.
has a financial relationship (Grant Or Contract) with Seagen;.
has a financial relationship (Grant Or Contract) with Fate Therapeutics;.
has a financial relationship (Grant Or Contract) with Bristol Myers Squibb;.
has a financial relationship (Grant Or Contract) with Bristol Myers Squibb;.
has a financial relationship (Grant Or Contract) with Ono Pharma;.
has a financial relationship (Grant Or Contract) with Curis Inc;.

Amandeep Godara, MD

has a financial relationship (Other) with Sanofi;.
has a financial relationship (Other) with Janssen;.

Kenneth Macdonald, MD

has no relevant financial relationships to disclose at this time.

Stephanie Moline, MD, FACS

has no relevant financial relationships to disclose at this time.

Mark Pegram, MD

has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Employment) with Rain Oncology;.

GEORGE RODGERS, MD, PhD

has a financial relationship (Other) with Argenx;.
has a financial relationship (Other) with Dova;.

Jennifer Specht, MD

has a financial relationship (Professional Services) with Sensei Biotherapeutics;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Abbvie ;.
has a financial relationship (Grant Or Contract) with Carisma Therapeutics;.
has a financial relationship (Professional Services) with GE Healthcare;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Celcuity;.
has a financial relationship (Grant Or Contract) with Lyell Immunopharma;.
has a financial relationship (Other) with A2 Biotherapeutics ;.
has a financial relationship (Grant Or Contract) with Seattle Genetics;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Professional Services) with Lyell Immunopharma Inc;.
has a financial relationship (Professional Services) with Volastra Therapeutics;.
has a financial relationship (Grant Or Contract) with Xencor;.
has a financial relationship (Grant Or Contract) with Necktar;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.

Tsewang Tashi

has a financial relationship (Professional Services) with PharmaEssentia;.
has a financial relationship (Professional Services) with Cogent Biosciences;.
has a financial relationship (Professional Services) with Blueprint Medicines;.
has a financial relationship (Professional Services) with CTI Biopharma;.

Roland Walter, MD PhD MS

has no relevant financial relationships to disclose at this time.

Mei Wei, MD

has a financial relationship (Other) with Gilead Science;.

Fengting Yan, MD

has no relevant financial relationships to disclose at this time.
Case Presenter(s)

Oliver Batson, MD

has no relevant financial relationships to disclose at this time.

Corliss Newman

has no relevant financial relationships to disclose at this time.

Doris Quon, MD, PhD

has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Professional Services) with NovoNordisk;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with CSL Behring;.
has a financial relationship (Professional Services) with Biomarin;.
has a financial relationship (Professional Services) with Octapharma;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Roche/Genentech;.

Kristine Rinn, MD

has no relevant financial relationships to disclose at this time.

Paul White, Paul S White, MD

has no relevant financial relationships to disclose at this time.
Moderator(s)

Akhanda Chintapatla, Physician,

has a financial relationship (Professional Services) with Kite Pharmaceuticals;.
has a financial relationship (Professional Services) with Biotheranostics;.
has a financial relationship (Professional Services) with AstraZeneca ;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Abbvie ;.
has a financial relationship (Professional Services) with Janssen ;.
has a financial relationship (Professional Services) with MJH Life Sciences ;.
has a financial relationship (Professional Services) with Curio Scioence LLC;.
has a financial relationship (Professional Services) with MorphoSys ;.
has a financial relationship (Professional Services) with GSK;.

Aaron Goodman, MD

has a financial relationship (Professional Services) with Seattle Genetics;.

Deepthi Kodali

has no relevant financial relationships to disclose at this time.

Fengting Yan, MD

has no relevant financial relationships to disclose at this time.

Available Credit

  • 8.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.25 Contact Hours.
Company NameExhibit typeExhibitor  Name2nd Rep  Name
ABBVIETable top ExhibitCatherine Simpson 
ADC TherapeuticsTable top ExhibitCandy Griffith 
AlexionTable top ExhibitFaith LarmayCurtis Nanney 
AstraZeneca Table top ExhibitVictoria MickelsonKaren Miller
AstraZeneca - HematologyTable top ExhibitJeff Tokish 
BeiGeneTable top ExhibitDoug Jordan 
Blueprint MedicinesTable top ExhibitMARK LIGHTNER 
CLL SocietyTable top ExhibitRobyn Brumble 
Daiichi Sankyo (DSI)Table top Exhibit Krystin Roberts 
Eli LillyTable top ExhibitShawn Hathaway 
ExelixisTable top ExhibitTed NiedermeyerRyan  Erlandson
Foundation MedicineTable top ExhibitTrent Roesch 
GenmabTable top ExhibitDerek Berquist 
Gilead SciencesTable top ExhibitGary RamosTina  Seidita
GSKTable top ExhibitBrendan Goehner 
Guardant HealthTable top ExhibitLara EstebJames Lillian
IncyteTable top ExhibitMichael Roh 
IpsenTable top ExhibitSteven Boiteux 
Jazz PharmaceuticalTable top ExhibitAllison Mallory 
Johnson & Johnson Innovative MedicineTable top ExhibitTravis  HarkenBrooke Breckenridge
MerckTable top ExhibitCalli LalimeSonya Rocha
MorphoSysTable top ExhibitKristanne  ClubbAnne Sherwood
NovartisTable top ExhibitCraig CarterChristine Emert
PfizerTable top ExhibitSusie Fenberg 
PharmacyclicsTable top ExhibitAnita Adams 
PharmaEssentiaTable top ExhibitAlicia MossTahna Fischer
SanofiTable top ExhibitDaniel BitterLinda Baker
SeaGenTable top ExhibitCarla TaylorBeth Williamson

 

 

Price

Cost:
$200.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.